| Year |
Citation |
Score |
| 2019 |
Muss HB, Polley MC, Berry DA, Liu H, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Kartcheske PA, Perez EA, Wolff AC, Gralow JR, et al. Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900647. PMID 31339827 DOI: 10.1200/Jco.19.00647 |
0.402 |
|
| 2019 |
Dressler LG, Bell GC, Schuetze DP, Steciuk MR, Binns OA, Raab RE, Abernathy PM, Wilson CM, Kunutsor SE, Loveless MC, Ahearne PM, Messino MJ. Implementing a personalized medicine cancer program in a community cancer system. Personalized Medicine. PMID 31109249 DOI: 10.2217/Pme-2018-0112 |
0.314 |
|
| 2016 |
Muluneh B, Deal A, Alexander MD, Keisler MD, Markey JM, Neal JM, Bernard S, Valgus J, Dressler LG. Patient perspectives on the barriers associated with medication adherence to oral chemotherapy. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. PMID 27895220 DOI: 10.1177/1078155216679026 |
0.334 |
|
| 2015 |
Dressler LG, Deal AM, Owzar K, Watson D, Donahue K, Friedman PN, Ratain MJ, McLeod HL. Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance). Journal of the National Cancer Institute. 107. PMID 26160883 DOI: 10.1093/Jnci/Djv188 |
0.381 |
|
| 2014 |
Dressler LG, Deal AM, Patel J, Markey J, Riper MV, McLeod HL. Cancer pharmacogenomics, adoption by oncologists and patient benefit. Personalized Medicine. 11: 143-153. PMID 29751378 DOI: 10.2217/Pme.14.1 |
0.364 |
|
| 2014 |
Dressler LG, Zeps N, Deal AM, Markey J, Knoppers B. Return of individual research results: Policies and experiences of cancer genomic researchers. Journal of Clinical Oncology. 32: 11025-11025. DOI: 10.1200/Jco.2014.32.15_Suppl.11025 |
0.345 |
|
| 2013 |
Dressler LG, Deal AM, Watson D, Hollis D, Owzar K, Donohue K, Friedman PN, Ratain MJ, McLeod HL. Participation in cancer pharmacogenomic studies in 8,456 patients registered to Cancer and Leukemia Group B (Alliance) clinical trials. Journal of Clinical Oncology. 31: 6501-6501. DOI: 10.1200/Jco.2013.31.15_Suppl.6501 |
0.347 |
|
| 2012 |
Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, ... ... Dressler L, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3242-9. PMID 22649152 DOI: 10.1200/Jco.2011.39.2779 |
0.432 |
|
| 2012 |
Peppercorn J, Shapira I, Deshields T, Kroetz D, Friedman P, Spears P, Collyar DE, Shulman LN, Dressler L, Bertagnolli MM. Ethical aspects of participation in the Database of Genotypes and Phenotypes of the National Center for Biotechnology Information: The Cancer and Leukemia Group B Experience Cancer. 118: 5060-5068. PMID 22415847 DOI: 10.1002/Cncr.27515 |
0.399 |
|
| 2012 |
Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, ... ... Dressler L, et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Research and Treatment. 132: 1049-62. PMID 22198468 DOI: 10.1007/S10549-011-1895-2 |
0.441 |
|
| 2012 |
Muluneh B, Alexander M, Deal AM, Deal M, Markey J, Neal J, Bernard SA, Valgus J, Dressler LG. Prospective evaluation of perceived barriers to medication adherence by patients on oral antineoplastics. Journal of Clinical Oncology. 30: 6042-6042. DOI: 10.1200/Jco.2012.30.15_Suppl.6042 |
0.395 |
|
| 2011 |
Lara JF, Thor AD, Dressler LG, Broadwater G, Bleiweiss IJ, Edgerton S, Cowan D, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, et al. p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 5170-8. PMID 21693655 DOI: 10.1158/1078-0432.Ccr-11-0484 |
0.419 |
|
| 2010 |
O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J, Millikan RC. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 6100-10. PMID 21169259 DOI: 10.1158/1078-0432.Ccr-10-1533 |
0.432 |
|
| 2010 |
Clayton EW, Smith M, Fullerton SM, Burke W, McCarty CA, Koenig BA, McGuire AL, Beskow LM, Dressler L, Lemke AA, Ramos EM, Rodriguez LL. Confronting real time ethical, legal, and social issues in the Electronic Medical Records and Genomics (eMERGE) Consortium. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 12: 616-20. PMID 20733502 DOI: 10.1097/Gim.0B013E3181Efdbd0 |
0.315 |
|
| 2010 |
Garber JE, Halabi S, Tolaney SM, Kaplan E, Archer L, Atkins JN, Edge S, Shapiro CL, Dressler L, Paskett ED, Paskett EM, Kimmick G, Orcutt J, Scalzo A, Winer E, et al. Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. Journal of the National Cancer Institute. 102: 942-9. PMID 20554945 DOI: 10.1093/Jnci/Djq211 |
0.434 |
|
| 2010 |
Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabé RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, Guttmacher A, Guyer M, Hemsley FM, Jennings JL, ... ... Dressler LG, et al. International network of cancer genome projects. Nature. 464: 993-8. PMID 20393554 DOI: 10.1038/Nature08987 |
0.359 |
|
| 2009 |
Dressler LG. Disclosure of research results from cancer genomic studies: state of the science. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4270-6. PMID 19549775 DOI: 10.1158/1078-0432.Ccr-08-3067 |
0.331 |
|
| 2009 |
Harris LN, Broadwater G, Abu-Khalaf M, Cowan D, Thor AD, Budman D, Cirrincione CT, Berry DA, Winer EP, Hudis CA, Hayes DF, Friedman P, Ellis M, Dressler L. Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3430-6. PMID 19470942 DOI: 10.1200/Jco.2008.18.4085 |
0.4 |
|
| 2009 |
Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. The New England Journal of Medicine. 360: 2055-65. PMID 19439741 DOI: 10.1056/Nejmoa0810266 |
0.451 |
|
| 2009 |
Livasy C, Carey L, DeMichele A, Cowan D, Markey J, Little D, Investigators IC, Dressler L. Influence of anthracycline- and taxane-based neoadjuvant chemotherapy on tumor HER2 protein expression in locally advanced breast cancers: results from the I-SPY TRIAL (CALGB 150007/150012 & ACRIN 6657). Cancer Research. 69: 703. DOI: 10.1158/0008-5472.Sabcs-703 |
0.4 |
|
| 2009 |
Livasy C, Carey L, DiMichelle A, Cowan D, Little D, Markey J, Moore D, Investigators IC, Dressler L. Biomarkers associated with pathologic complete response to neoadjuvant chemotherapy in women with locally advanced breast cancer: results from the I-SPY TRIAL (CALGB 150007/150012 & ACRIN 6657). Cancer Research. 69: 5102. DOI: 10.1158/0008-5472.Sabcs-5102 |
0.471 |
|
| 2008 |
DiGiovanna MP, Stern DF, Edgerton S, Broadwater G, Dressler LG, Budman DR, Henderson IC, Norton L, Liu ET, Muss HB, Berry DA, Hayes DF, Thor AD. Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2364-72. PMID 18390970 DOI: 10.1200/Jco.2007.13.6580 |
0.334 |
|
| 2008 |
Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, et al. Epidemiology of basal-like breast cancer. Breast Cancer Research and Treatment. 109: 123-39. PMID 17578664 DOI: 10.1007/S10549-007-9632-6 |
0.31 |
|
| 2008 |
Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, et al. Epidemiology of basal-like breast cancer (Breast Cancer Research and Treatment DOI: 10.1007/s10549-007-9632-6) Breast Cancer Research and Treatment. 109: 141. DOI: 10.1007/S10549-007-9790-6 |
0.428 |
|
| 2007 |
Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, et al. HER2 and response to paclitaxel in node-positive breast cancer. The New England Journal of Medicine. 357: 1496-506. PMID 17928597 DOI: 10.1056/Nejmoa071167 |
0.425 |
|
| 2006 |
Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, Hayes DF, Winer EP, Dressler L. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Research : Bcr. 8: R66. PMID 17129383 DOI: 10.1186/Bcr1622 |
0.404 |
|
| 2006 |
Kelly H, Kimmick G, Dees EC, Collichio F, Gatti L, Sawyer L, Ivanova A, Dressler L, Graham ML, Carey LA. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide. Clinical Breast Cancer. 7: 237-43. PMID 16942640 DOI: 10.3816/Cbc.2006.N.035 |
0.384 |
|
| 2006 |
Rincon M, Broadwater G, Harris L, Crocker A, Weaver D, Dressler L, Berry D, Sutton L, Michaelson R, Messino M, Kirshner J, Fleming G, Winer E, Hudis C, Appel S, et al. Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. Breast Cancer Research and Treatment. 100: 301-8. PMID 16773437 DOI: 10.1007/S10549-006-9251-7 |
0.379 |
|
| 2006 |
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Jama. 295: 2492-502. PMID 16757721 DOI: 10.1001/Jama.295.21.2492 |
0.426 |
|
| 2006 |
Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, et al. The molecular portraits of breast tumors are conserved across microarray platforms. Bmc Genomics. 7: 96. PMID 16643655 DOI: 10.1186/1471-2164-7-96 |
0.41 |
|
| 2005 |
Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S, Miller A, Tse J, Novotny D, Persons DL, Barcos M, Henderson IC, Liu ET, Thor A, Budman D, et al. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4287-97. PMID 15994142 DOI: 10.1200/Jco.2005.11.012 |
0.465 |
|
| 2005 |
Lark AL, Livasy CA, Dressler L, Moore DT, Millikan RC, Geradts J, Iacocca M, Cowan D, Little D, Craven RJ, Cance W. High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype Modern Pathology. 18: 1289-1294. PMID 15861214 DOI: 10.1038/Modpathol.3800424 |
0.409 |
|
| 2005 |
Garber JE, Halabi S, Kaplan E, Edge S, Dressler L, Paskett E, Berliner N. Factor V Leiden (FVL) mutations and thromboembolic events (TE) in women with breast cancer on adjuvant tamoxifen Journal of Clinical Oncology. 23: 508-508. DOI: 10.1200/Jco.2005.23.16_Suppl.508 |
0.343 |
|
| 2005 |
Jewell SD, Monovich LC, Edgerton S, Schilsky RL, Dressler LG. Biospecimen Banking, Standardization, and Lessons Learned from the Cancer and Leukemia Group B Pathology Coordinating Office Seminars in Breast Disease. 8: 93-99. DOI: 10.1053/J.Sembd.2006.06.006 |
0.379 |
|
| 2004 |
Lin NU, Broadwater G, Dressler LG, Schnitt S, Lara J, Bleiweiss I, Ngo T, Miron A, Winer E, Harris LN. The predictive value of HER2 and p53 on outcomes after paclitaxel chemotherapy for metastatic breast cancer: Results from CALGB 9342. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 9562. PMID 28016843 DOI: 10.1200/Jco.2004.22.14_Suppl.9562 |
0.426 |
|
| 2004 |
Lightfoot HM, Lark A, Livasy CA, Moore DT, Cowan D, Dressler L, Craven RJ, Cance WG. Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis Breast Cancer Research and Treatment. 88: 109-116. PMID 15564794 DOI: 10.1007/S10549-004-1022-8 |
0.354 |
|
| 2004 |
Usary J, Llaca V, Karaca G, Presswala S, Karaca M, He X, Langerød A, Kåresen R, Oh DS, Dressler LG, Lønning PE, Strausberg RL, Chanock S, Børresen-Dale AL, Perou CM. Mutation of GATA3 in human breast tumors. Oncogene. 23: 7669-78. PMID 15361840 DOI: 10.1038/Sj.Onc.1207966 |
0.363 |
|
| 2004 |
Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 5367-74. PMID 15328174 DOI: 10.1158/1078-0432.Ccr-04-0220 |
0.437 |
|
| 2004 |
Chung CH, Parker JS, Karaca G, Wu J, Funkhouser WK, Moore D, Butterfoss D, Xiang D, Zanation A, Yin X, Shockley WW, Weissler MC, Dressler LG, Shores CG, Yarbrough WG, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell. 5: 489-500. PMID 15144956 DOI: 10.1016/S1535-6108(04)00112-6 |
0.309 |
|
| 2003 |
Furberg H, Millikan RC, Geradts J, Gammon MD, Dressler LG, Ambrosone CB, Newman B. Reproductive factors in relation to breast cancer characterized by p53 protein expression (United States) Cancer Causes and Control. 14: 609-618. PMID 14575358 DOI: 10.1023/A:1025682410937 |
0.427 |
|
| 2003 |
Millikan R, Eaton A, Worley K, Biscocho L, Hodgson E, Huang WY, Geradts J, Iacocca M, Cowan D, Conway K, Dressler L. HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. Breast Cancer Research and Treatment. 79: 355-64. PMID 12846420 DOI: 10.1023/A:1024068525763 |
0.397 |
|
| 2002 |
Stitzenberg KB, Calvo BF, Iacocca MV, Neelon BH, Sansbury LB, Dressler LG, Ollila DW. Cytokeratin immunohistochemical validation of the sentinel node hypothesis in patients with breast cancer. American Journal of Clinical Pathology. 117: 729-37. PMID 12090421 DOI: 10.1309/7606-F158-Ugjw-Yble |
0.339 |
|
| 2001 |
Page DL, Gray R, Allred DC, Dressler LG, Hatfield AK, Martino S, Robert NJ, Wood WC. Prediction of node-negative breast cancer outcome by histologic grading and S-phase analysis by flow cytometry: An Eastern Cooperative Oncology Group study (2192) American Journal of Clinical Oncology: Cancer Clinical Trials. 24: 10-18. PMID 11232942 DOI: 10.1097/00000421-200102000-00002 |
0.443 |
|
| 2000 |
Simpson JF, Gray R, Dressler LG, Cobau CD, Falkson CI, Gilchrist KW, Pandya KJ, Page DL, Robert NJ. Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 2059-69. PMID 10811671 DOI: 10.1200/Jco.2000.18.10.2059 |
0.457 |
|
| 2000 |
Dressler LG, Thor AD. HER2 testing: Laboratory, technical and clinical considerations Breast Disease. 11: 77-87. DOI: 10.3233/Bd-1999-11107 |
0.371 |
|
| 1999 |
Dressler LG, Geradts J, Burroughs M, Cowan D, Millikan RC, Newman B. Policy guidelines for the utilization of formalin-fixed, paraffin-embedded tissue sections: The UNC SPORE experience Breast Cancer Research and Treatment. 58: 31-39. PMID 10634516 DOI: 10.1023/A:1006354627669 |
0.319 |
|
| 1995 |
Millikan R, Dressler L, Geradts J, Graham M. The need for epidemiologic studies of in-situ carcinoma of the breast Breast Cancer Research and Treatment. 35: 65-77. PMID 7612906 DOI: 10.1007/Bf00694747 |
0.406 |
|
| 1993 |
Dressler LG. DNA flow cytometry measurements and their clinical relevance in node-negative breast cancer patients Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer. 127: 61-69. PMID 8502831 |
0.314 |
|
| 1993 |
Kesterson L, Shelton C, Dressler L, Berliner KI. Clinical Behavior of Acoustic Tumors: A Flow Cytometric Analysis Archives of Otolaryngology-Head & Neck Surgery. 119: 269-271. PMID 8435163 DOI: 10.1001/Archotol.1993.01880150017002 |
0.305 |
|
| 1993 |
Dressler LG. DNA flow cytometry measurements as surrogate endpoints in chemoprevention trials: clinical, biological, and quality control considerations Journal of Cellular Biochemistry. Supplement. 17: 212-218. PMID 8007701 DOI: 10.1002/Jcb.240531139 |
0.393 |
|
| 1992 |
Clark GM, Mathieu MC, Owens MA, Dressler LG, Eudey L, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff MD. Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 10: 428-32. PMID 1740681 DOI: 10.1200/Jco.1992.10.3.428 |
0.418 |
|
| 1992 |
Dressler LG. Are DNA Flow Cytometry Measurements Providing Useful Information in the Management of the Node-Negative Breast Cancer Patient? Cancer Investigation. 10: 477-486. PMID 1393694 DOI: 10.3109/07357909209024806 |
0.392 |
|
| 1989 |
Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T, McGuire WL. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry New England Journal of Medicine. 320: 627-633. PMID 2918874 DOI: 10.1056/Nejm198903093201003 |
0.422 |
|
| 1988 |
Dressler LG, Seamer LC, Owens MA, Clark GM, McGuire WL. DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens Cancer. 61: 420-427. PMID 3338012 |
0.31 |
|
| 1986 |
Dressler LG, Edwards DP, Grzyb KT, Mansel RE, Zava DT, Sledge GW, McGuire WL. Monoclonal Antibody Identification and Characterization of a Mr43,000 Membrane Glycoprotein Associated with Human Breast Cancer Cancer Research. 46: 1306-1317. PMID 3510721 |
0.309 |
|
| 1985 |
McGuire WL, Dressler LG. Emerging impact of flow cytometry in predicting recurrence and survival in breast cancer patients Journal of the National Cancer Institute. 75: 405-410. PMID 3861896 |
0.339 |
|
| Show low-probability matches. |